Multiple research studies have indicated that the current biomarkers for predicting the efficacy of ICIs in HCC include PD-L1 expression level, TMB, circulating tumor DNA, dMMR and MSI [10, 25]. Here, CD274 is linked to hepatocellular carcinoma.